Lupin receives USFDA nod for Suprax oral suspension

Health

Drug firm Lupin today said it has received approval from the US health regulator for its Suprax oral suspension used for treating bacterial infections and expects to commence shipping the product in the near future.

The company's subsidiary Lupin Pharmaceuticals Inc has received approval for Suprax for oral suspension in the strength of 500mg/5mL from the United States Food and Drugs Administration (USFDA), Lupin said in a statement.

"Suprax is currently available as 100 mg/5ml and 200 mg/5ml suspensions, 400 mg tablets as well as chewable tablets 100 & 200 mg," the Mumbai based company said.

Commenting on the approval, Lupin Ltd Group President & Lupin Pharmaceutical Inc CEO Vinita Gupta said: "The new dosage form will add to our growing Suprax franchise and gives health care providers and patients a new formulation to treat the indicated infections."

"This new drug application provides for a new strength 500 mg/5mL of Suprax (cefixime) for the treatment of otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections (cervical/urethral), uncomplicated gonorrhoea and pharyngitis/tonsillitis," the company said.

Shares of Lupin Ltd were today trading at Rs 599.85 per scrip on BSE, up 0.98 per cent from its previous close.

Stocks More on Lupin Ltd

Please read our terms of use before posting comments
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
comments powered by Disqus